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be difﬁcult for patients with co-morbidities. To reduce these toxicities, 
we conducted a phase II study to evaluate the efﬁcacy and toxicity of 
weekly cisplatin and docetaxel in advanced NSCLC.
Methods: Eligibility included patients with advanced or recurrent 
NSCLC, ECOG PS of 0-1, and no prior chemotherapy for metastatic 
disease. This Cancer Institute of New Jersey network, single stage 
phase II clinical trial was designed to give 3 weekly doses of cisplatin 
at 25 mg/m2 and docetaxel at 35 mg/m2, followed by 1 week of rest, 
for a total of 6 cycles of therapy. Toxicity was monitored weekly, and 
disease evaluation was performed every 2 cycles. The primary endpoint 
was response rate (RR); secondary endpoints included time to progres-
sion (TTP), median and 1-year survival. 
Results: From 12/03 to 03/07, 38 patients were enrolled so far. The 
median age of patients is 63 (range 47-78), the majority is white 
(n=35), 31 have stage IV disease, and almost half (n=18) are women. 
Fifteen have an ECOG PS=0 and 23 with PS=1. Histologic subtypes 
are: adenocarcinoma (n=26), NSCLC NOS (n=7), squamous (n=5). 
Fourteen patients received ? 4 cycles of therapy; median number of 
cycles delivered is 2.4. Reasons for treatment discontinuation include 
completion of therapy (n=7), progression of disease (n=17), adverse 
events (n=8), and patient preference (n=4). Two patients continue on 
therapy at this time. No complete responses were yet observed; 8 pa-
tients (21%) achieved a partial response; 10 patients had stable disease, 
10 patients progressed, 8 came off study before ﬁrst disease evaluation, 
and 2 have not yet had disease evaluation. Median TTP was 3.8 months 
(mo) (95% CI 2.0, 4.7), median survival is 8.7 mo (95% CI 5.6,16.2) 
and 1-year survival is 40.2% (95% CI 20.9, 58.8). Most toxicities 
were mild but also included neutropenia (grade 3, n=1; grade 4, n=1), 
neutropenic fever (n=1), renal toxicity (grade 3, n=2), nausea (grade 
3, n=1), fatigue (grade 3, n=3), diarrhea (grade 3, n=4) and metabolic 
abnormalities (grade 3, n=3). 
Conclusion: Weekly cisplatin and docetaxel is well tolerated with a 
low incidence of toxicity and demonstrates activity similar to every 
3-week treatment in patients with advanced NSCLC.
P2-226 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4 
The Portuguese experience with pemetrexed (ALIMTA) in second 
line treatment of non-small cell lung cancer
Araujo, António M.1 Barata, Fernando2 Parente, Bárbara3 Rego, Sónia1 
Teixeira, Encarnação4 Melo, Maria J.5 Queiroga, Henrique6 Cunha, 
João7 Duarte, José8 
1 Portuguese Institute of Oncology - Porto Centre, Porto, Portugal 2 
Centro Hospitalar de Coimbra, Coimbra, Portugal 3 Centro Hospi-
talar V. N. Gaia, V. N. Gaia, Portugal 4 Hospital Santa Maria, Lisboa, 
Portugal 5 Hospital Pulido Valente, Lisboa, Portugal 6 Hospital S. 
João, Porto, Portugal 7 Hospital S. Marcos, Braga, Portugal 8 Hospital 
Garcia Orta, Almada, Portugal 
On behalf of the Portuguese Lung Cancer Study Group 
Background: Unitl 2004, docetaxel in monotherapy was the standard 
for second-line treatment of non-small cell lung cancer (NSCLC). 
Pemetrexed (P), an multi-target antifolate, with vitamin supplementa-
tion, has shown similar activity in this setting with a better adverse 
event proﬁle (Hanna N et al, J Clin Oncol 2004;22:1589-1597). In 
Portugal, it was introduced in October of 2004 for second-line mono-
therapy. We have carried out a retrospective analysis of patients who 
received P for second-line NSCLC in Portugal from October 2004 to 
December 2006.
Methods: Data were collected retrospectively from the records of 
patients (pts) enrolled in centers participating in the Portuguese Lung 
Cancer Study Group (GECP). The pts had locally advanced or meta-
static NSCLC and failed ﬁrst-line chemotherapy. They received P (500 
mg/m2 on a three-weekly schedule with vitamin supplementation). 
Objective response (OR; complete [CR] or partial [PR] response) was 
evaluated using RECIST and safety assessed using serious or non-seri-
ous adverse events (SAEs/AEs).
Results: By December 2006, 19 GECP centers had enrolled 244 
pts who had received P for ≥1 cycle, and were considered evaluable 
for both objective response and safety. Demography: male/female, 
175/69; median age, 57.0 years (range 20-81); smoking status, y/ex/n, 
116/57/71 adenocarcinoma/squamous-cell carcinoma/other histology, 
141/72/31; prior chemotherapy, platin plus gemcitabine/paclitaxel/
vinorelbine/docetaxel, 152/37/30/19; mean number of cycles in 1st 
line, 4.8 (range 1-8); disease control (OR + stable disease [SD]) was 
observed in 170 (61.0%) pts: 7 CR, 79 PR and 84 SD; mean time to 
progression (TTP) 8.07 months. P mean number of cycles in 2nd line, 
4.1 (range1-15); disease control in 209 evaluable pts was observed in 
116 (55.5%): 2 CR, 45 PR and 69 SD; mean TTP 4.70 months. The 
majority of AEs were grade 3 anemia (15 pts) and neutropenia (18 pts). 
The mean overall survival was 17.27 months.
Conclusions: Our retrospective analysis has observed a similar disease 
control rate with P in 2nd line (55.5%), and TTP (4.7 months) in our 
current unselected population to that published in the literature. P is an 
option for second-line NSCLC with a good tolerability.
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Background: Docetaxel (D) and Pemetrexed (P) are two options for 
the second-line treatment of non small-cell lung cancer (NSCLC), 
with similar response rates and overall survivals but different toxicity 
(Hanna N et al, J Clin Oncol 2004;22:1589-1597). P was introduced 
in Portugal in October 2004. The authors carried out a retrospective 
study of patients (pts) diagnosed with NSCLC treated in 2nd line with 
D or P at Portuguese Institute of Oncology - Porto Centre (IPO-Porto), 
Portugal.
Methods: We made a retrospective review of the pt clinical ﬁles with 
NSCLC treated in second-line with D or P between December 2003 
and December 2006 at IPO-Porto. The primary objective was the 
evaluation of safety assessed using serious or non-serious adverse 
events. Secondary objectives were to assess time to progression (TTP) 
and overall survival (OS) between the two drugs on that unselected 
population.
Results: Of 96 evaluated pts who received 2nd line chemotherapy 
(CT), 78% were male. Median age at diagnosis was 63 years (range: 
29-81); 38% were adenocarcinomas, 58% squamous cell carcinoma 
and 4% were large cell carcinomas; 99% had a performance status 
ECOG 0. At diagnosis, 50% had metastasis in at least one site. All pts 
received platin ﬁrst line based CT. At 2nd line treatment, 77 (80%) re-
ceived D and 19 (20%) P. Mean number of cycles received was 5.6 for 
D and 4.3 for P. The sum of grade III toxicities were observed on 27 pts 
on D and 7 on P, and grade IV toxicities were observed on 10 pts on D 
and none on P. Incidence of grade III anaemia was 12% on D and 11% 
